HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Serenella M. Pupa; Elda Tagliabue; Sylvie Ménard; Andrea Anichini

doi:10.1002/jcp.20387

HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Serenella M. Pupa, Elda Tagliabue, Sylvie Ménard, Andrea Anichini

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article

Abstract

The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

Original language	English
Pages (from-to)	10-18
Number of pages	9
Journal	Journal of Cellular Physiology
Volume	205
Issue number	1
DOIs	https://doi.org/10.1002/jcp.20387
Publication status	Published - Oct 2005

ASJC Scopus subject areas

Clinical Biochemistry
Cell Biology
Physiology

Access to Document

10.1002/jcp.20387

Fingerprint Dive into the research topics of 'HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine'. Together they form a unique fingerprint.

Cite this

Pupa, S. M., Tagliabue, E., Ménard, S., & Anichini, A. (2005). HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. Journal of Cellular Physiology, 205(1), 10-18. https://doi.org/10.1002/jcp.20387

@article{207f0ef740164a8aa4b850501b4f232b,

title = "HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine",

abstract = "The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.",

author = "Pupa, {Serenella M.} and Elda Tagliabue and Sylvie M{\'e}nard and Andrea Anichini",

year = "2005",

month = oct,

doi = "10.1002/jcp.20387",

language = "English",

volume = "205",

pages = "10--18",

journal = "Journal of cellular and comparative physiology",

issn = "0021-9541",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - HER-2

T2 - A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

AU - Pupa, Serenella M.

AU - Tagliabue, Elda

AU - Ménard, Sylvie

AU - Anichini, Andrea

PY - 2005/10

Y1 - 2005/10

N2 - The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

AB - The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=24344474832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344474832&partnerID=8YFLogxK

U2 - 10.1002/jcp.20387

DO - 10.1002/jcp.20387

M3 - Article

C2 - 15887236

AN - SCOPUS:24344474832

VL - 205

SP - 10

EP - 18

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 1

ER -